News & Updates

Show Multimedia Only
Studies support vedolizumab benefit for IBD

Studies support vedolizumab benefit for IBD

07 Feb 2023 byAudrey Abella

Data presented at the Crohn’s & Colitis Congress (CCC) 2023 reflect the benefit of vedolizumab for inflammatory bowel disease (IBD; Crohn’s disease and ulcerative colitis), be it alone or in a combination regimen. In one study however, extraintestinal manifestations were observed following vedolizumab use.

07 Feb 2023
5-ASA use in paediatric CD common, deviates from recommended practices

5-ASA use in paediatric CD common, deviates from recommended practices

07 Feb 2023 byJairia Dela Cruz

Children with Crohn’s disease (CD) are often treated with 5-aminosalicylate (5-ASA) contrary to guidelines, and this practice is associated with a substantial delay in initiating biologic therapy, according to a study presented at this year’s Crohn's & Colitis Congress.

07 Feb 2023